Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$72MCash, Pro Forma
54.5mo Cash Runway
Follow EQ by emailGet an email when EQ reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about EQ, unsubscribe in one click. Privacy
📣 What EQ Says Is Next
second half of 2027 · “Subject to supportive results, Equillium plans to initiate a placebo-controlled proof-of-concept study in patients with moderately to severely active ulcerative colitis in the second half of 2027.”
Company press release, Nov 12, 2026 · SEC filing
second quarter of 2027 · “Equillium expects to report topline data, including proof-of-mechanism assessments, in the second quarter of 2027.”
Company press release, Nov 12, 2026 · SEC filing
second half of 2027 · EQ504: “We look forward to reporting proof-of-mechanism data in the second quarter of 2027, which we expect will inform our planned proof-of-concept study in ulcerative colitis that we expect to initiate in the second half of 2027.”
Company press release, Nov 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Earnings Reported Q3 2026 results: cash equivalents of $53.3 million at September 30, 2026, and a pro forma balance of about $72.0 million after a $20 million second tranche closed in October. Net loss was $4.6 million, or $(0.04) per share, and cash runway is expected into 2029. Form 8-K · SEC filing · Press release
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Financing Equillium is registering for resale up to 35,087,717 shares of common stock, including 20,130,457 shares issuable on pre-funded warrants, sold in an October 26, 2026 private placement of 14,957,260 shares and pre-funded warrants. The company receives no proceeds from the resales. Form S-3 · SEC filing
Oct 26, 2026 ·
Financing Equillium dosed the first subject in its Phase 1 trial of EQ504 in Australia, triggering a $20.0 million milestone closing of 14,957,260 shares at $0.57 and 20,130,457 pre-funded warrants at $0.5669. Cash is expected to fund planned operations into 2029. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Earnings Reported Q2 2026 results: cash of $57.2 million, funding operations into 2029, with a net loss of $4.7 million, or $(0.04) per share. Phase 1 EQ504 study expected to start in Q4 2026, with topline data about six months later. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Apr 2027 · Phase 1 · Upcoming Trial · A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy Volunteers Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not EQ's own candidates): IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
EQ had $53.3M in cash and short-term investments on its Sep 30, 2026 balance sheet.
Including the cash events since then, it holds about $72M pro forma, before operating spending after that date:
Company-stated pro forma cash at Sep 30, 2026 (release of Nov 12, 2026): $72M in total · 8-K
It burns about $4M/quarter from operations, an estimated runway of 54.5 months from Sep 30, 2026 at that rate (BioRadar estimate, not company guidance).
Dilution pressure:24 · Moderate
Cash runway 54 months (pro forma for cash events since the balance sheet)
ATM program on file since Nov 2025 +15
Shelf registration (S-3, Nov 2025) +10
Company says cash lasts into 2029 -15We expect that our existing cash and cash equivalents as of September 30, 12 2026, together with the net proceeds from the October 2026 Milestone Closing, will enable us to fund our operations into 2029.10-Q, Nov 2026
Share count 82,324,700 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full EQ picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EQ and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.